Friday, 12 April 2024

Breakthrough antibiotic by Singapore shows promise against obstinate mycobacterial infections

28 March 2024 | News

Offering a more effective therapeutic option against hard-to-treat mycobacterial lung diseases

Researchers from the Institute for Functional Intelligent Materials (I-FIM) at the National University of Singapore (NUS) have innovated a conjugated oligoelectrolyte (COE)-based compound that has the potential to turn the tide on the nontuberculous mycobacteria infections.

Called COE-PNH2, this novel agent not only demonstrates high efficacy against Mycobacterium abscessus (Mab), one of the most prevalent mycobacteria species, but also shows a blend of potency and safety that could reshape the treatment paradigm for persistent lung infections.

A class of antimicrobial compounds with a modular molecular framework, COEs can be engineered into a panoply of therapeutic agents to fight a broad spectrum of infections.

COE-PNH2, the molecule designed and crafted by the I-FIM researchers, is optimised to target Mab, employing a dual mechanism that disrupts the bacterial membrane and obstructs vital bioenergetic pathways, a one-two punch that leaves the bacteria with little room to hide. In particular, the molecule attacks both replicating and dormant forms of Mab, exhibiting robust bactericidal activity that leads to a more comprehensive eradication of the bacteria, leaving no refuge for resistance to crop up while reducing the likelihood of relapse.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account